We previously demonstrated that salinomycin, which targets breast cancer stem cells (CSCs) [10], inhibits VM activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer cell lines and clinical samples. This evidence concerns the gene ERBB2 and breast carcinoma.